Construction of an engineered Escherichia coli with enhanced intestinal colonization and anti-inflammatory efficacy in colitis
Yu, P.; Zhou, W.; Li, C.; Sun, Q.; Yang, Y.
Show abstract
Engineered probiotics are considered as effective and safe therapeutic strategies for the treatment of various diseases. Escherichia coli Nissle 1917 (EcN) has been widely used as a chassis strain for its safety and well-established genetic manipulation system. The limited intestinal colonization ability of EcN hampers its potential as a chassis for constructing synthetic probiotics in therapeutic applications. Here, an engineered EcN strain with high gastric acid and bile salts tolerance as well as enhanced intestinal adhesion ability was constructed by improving the expression of gastric acid and bile salts tolerance-associated genes and strengthening the expression of curli fiber formation genes, respectively. Meanwhile, oral administration of this engineered strain to colitis mice alleviated the disease severity and restored the disordered gut microbiome by decreasing the abundance of Escherichia-Shigella, whereas increasing norank_f_Muribaculaceae. We engineered EcN to improve its probiotic properties and anti-colitis efficacy, thereby establishing a platform for precision-designed synthetic probiotics.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Akkermansia muciniphila identified as key strain to alleviate gut barrier injury through Wnt signaling pathway 96%
- Microbiota from young mice counteracts susceptibility to age-related gout through modulating butyric acid levels in aged mice 94%
- CD131 Contributes to Ulcerative Colitis Pathogenesis by Promoting Macrophage Infiltration 94%
Similar papers in this journal
- Integrated characterization of SARS-CoV-2 genome, microbiome, antibiotic resistance and host response from single throat swabs 92%
- Reprogramming an RNA-guided archaeal TnpB endonuclease for genome editing 91%
- Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2 91%